Overview

Dose-ranging Study of SKF7™ for Obesity

Status:
Completed

Trial end date:
2021-05-22

Target enrollment:
0

Participant gender:
All

Summary

This study has been designed as a randomized, double blinded, multi-centric, placebo controlled, and phase II dose-ranging study. The herbal drug contains bioactive ingredients from Labisia pumila plant and it is an aqueous ethanolic standardized extract (SKF7™).

Phase:

Phase 2

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Indonesia University

Collaborator:

Medika Natura Sdn Bhd

Criteria

Inclusion Criteria:

1. Men aged 18 - 50 yrs or women aged 18 until before perimenopause, with obesity

2. Willing to participate in the study by signing the informed consent

3. Healthy by anamnesis

4. Agreed to maintain their current lifestyles (no changes in their diet and physical
exercise) during the clinical trial period.

Exclusion Criteria:

1. Positive result for Rapid test for COVID-19 at screening period.

2. Known hypersensitivity to any herbal product.

3. Pregnant or lactating women.

4. Taking any other weight loss therapy and/or lipid lowering products.

5. Participate in other interventional clinical study or have taken other investigational
drug within 30 days prior to screening.